DGEN Deltagen Inc. featured news, full reports, and detailed charts
Deltagen Inc. (DGEN/DGEN.PK) Wrap Up:
Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was founded in 1997 and is headquartered in San Mateo, California.Deltagen Inc. (DGEN:OTC)
|
Market Cap
--
|
Total Revenue
1.5M
|
|
|
EBITDA
388.0K
|
DILUTED EPS TTM
--
|
|
|
P/E
--
|
P/S
--
|
|
|
Return On Asset
-3.46
|
Return On Equity
-6.98
|
|
| K = Thousands M = Millions B = Billions | ||
DGEN Top Compensated Officers
Executives, Board Directors
Key developments for Deltagen Inc. (DGEN)
Deltagen Inc. reported unaudited consolidated financial results for the second quarter ended June 30, 2009. For the quarter, the company's revenues were $0.282 million. The revenues were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOneTM program. Interest income was $0.004 million. Net loss before provision for income taxes and net income after taxes was $0.149 million. Income from operations was $0.153 million.
Deltagen Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2009. For the quarter, the company reported that consolidated revenues totaled $0.264 million. The revenues were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOneTM program. Net loss before provision for income taxes was $0.068 million. Income from operations was $0.075 million. Income before provision for income taxes was $0.068 million. Net increase/decrease in cash from operations was $0.056 million.
Deltagen Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2008. For the quarter, the company reported net loss of $387,000 on revenue of $458,000. The company also reported loss before provision for income taxes was $269,000. Loss from opertions was $289,000. The revenues in the fourth quarter were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOneTM program. For the full year, the company reported net income of $37,000 on revenue of $2,926,000. The company also reported income before provision for income taxes was $155,000. Income from opertions was $69,000.
DGEN Competitors
| Company | Last | Change |
| Caliper Life Sciences Inc | $2.70 USD | 0.00 |
| Exelixis Inc | $6.71 USD | +0.08 |
| Genoway | €2.91 EUR | -0.04 |
| Lexicon Pharmaceuticals Inc | $1.50 USD | +0.01 |
| Ore Pharmaceutical Holdings Inc | $0.53 USD | -0.10 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | DGEN | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
DGEN |
||
DGEN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Deltagen Inc.
More news for DGEN
Deltagen Reports 2009 Second Quarter Financial Results
DELTAGEN, INC. CONSOLIDATED BALANCE SHEET (UNAUDITED)   Consolidated Balance Sheet For Quarter Ended 6/30/09 Unaudited  (Dollars In Thousands) 6/30/09 Consolidated Assets Current assets: Cash and cash equivalents 4,702 Accounts receivable, net 221 Prepaids, Deposits and Tax Assets 45 ...Click here to read the whole Article (external link)